Where Connected Pharmacovigilance Is Headed Next

Pharmaceutical Commerce's conversation with Vikram Anand, president of compliance services at EVERSANA, on pharmacovigilance (PV) infrastructure closes with a look at what connected safety systems mean for the people ultimately affected by launch delays and drug safety issues: physicians and patients. In previous installments, Anand examined how PV gaps contribute to complete response letters and the operational blind spots behind them. In this final segment, he explains how a connected PV system changes outcomes on the ground, and where PV infrastructure is headed next.

Anand argues that a connected safety system turns PV from a paperwork exercise into a predictive shield, enabling faster signal detection, faster guidance to physicians and faster action. That matters, he says, because physicians extend access to companies that behave as reliable partners, delivering safety information consistently and at the right time. He walks through how this plays out operationally, tracing how medical information teams, which field HCP and patient questions through channels like medical inquiry lines, must work in coordination with PV and quality teams so that adverse events and product complaints surface quickly rather than getting siloed. When that handoff works, he says, it produces faster guidance, safer patients and greater trust in the therapy.

Looking ahead, Anand points to full automation at the intake level as the next phase for PV, with AI and natural language processing extracting adverse events from emails, literature and digital channels in place of manual review. He connects this shift to the industry's broader move toward personalized medicine, cell and gene therapy, where small patient populations and long study timelines make real-world evidence essential, requiring predictive signal detection systems that can adapt to new drug classes. Manufacturers who build adaptive, intelligent intake and triage now, he says, will be better positioned for regulatory audits and faster to get therapies to patients.

Watch the previous installments of Anand’s interview with PC:

1. Vikram Anand on the "Hidden Gatekeeper" Behind Commercial Delays
2. When PV Infrastructure Fails, Commercial Launches Pay the Price